Date |
Product |
Disease |
Phase |
Company |
Therapeutic area |
2016-04-12
|
HMPL-689 |
|
1 |
Hutchison China MediTech Limited (China) |
Cancer - Oncology |
2016-04-12
|
AB-PA01 (Pseudomonas aeruginosa bacteriophages) |
Pseudomonas aeruginosa infections in cystic fibrosis patients |
preclinical |
AmpliPhi BioSciences (USA - VA) |
Infectious diseases - Rare diseases |
2016-04-11
|
dipraglurant (ADX48621) |
levodopa-induced dyskinesia (LID) in Parkinson's disease (PD) patients |
1 |
Addex Therapeutics (Switzerland) Johns Hopkins University (USA - MD) |
Neurodegenerative diseases |
2016-04-11
|
brigatinib (AP26113) |
ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously been treated with an ALK inhibitor |
3 |
Ariad Pharmaceuticals (USA - MA) |
Cancer - Oncology |
2016-04-11
|
Epidiolex® (cannabidiol (2-[(1R,6R)-3-Methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol) |
tuberous sclerosis complex |
3 |
GW Pharmaceuticals (UK) |
Cancer - Oncology - Rare diseases |
2016-04-11
|
lefamulin (BC 3781) |
community-acquired bacterial pneumonia |
3 |
Nabriva Therapeutics (Austria) |
Infectious diseases |
2016-04-11
|
Epicutaneous Immunotherapy (EPIT), oral immunotherapy (OIT) and sublingual immunotherapy (SLIT) |
peanut allergy |
preclinical |
DBV Technologies (France) |
Allergic diseases |
2016-04-08
|
AZD3293/LY3314814 |
Alzheimer´s disease |
2-3 |
AstraZeneca (UK) Eli Lilly (USA - IN) |
Neurodegenerative diseases |
2016-04-07
|
CVT 301 (levodopa inhalation powder) |
idiopathic Parkinson's disease |
3 |
Acorda Therapeutics (USA - NY) |
Neurodegenerative diseases |
2016-04-07
|
MOR106 |
inflammation |
1 |
Galapagos (Belgium) Morphosys (Germany) |
Inflammatory diseases |
2016-04-07
|
trofinetide - NNZ-2566 - glycyl-L-2-methylprolyl-L-glutamic acid |
Rett syndrome |
2 |
Neuren Pharmaceuticals (Australia) |
Rare diseases |
2016-04-07
|
MVX-ONCO-1 |
solid tumors |
1 |
Maxivax (Switzerland) |
Cancer - Oncology |
2016-04-06
|
BIND-014 (docetaxel encapsulated in a polymeric nanoparticle) |
urothelial carcinoma, cholangiocarcinoma, cervical cancer, squamous cell carcinoma of head and neck |
2 |
Bind Therapeutics (USA - MA) |
Cancer - Oncology |
2016-04-06
|
BIND-014 (docetaxel encapsulated in a polymeric nanoparticle) |
non-small cell lung cancer (NSCLC) |
2 |
Bind Therapeutics (USA - MA) |
Cancer - Oncology |
2016-04-06
|
GLPG1690 |
idiopathic pulmonary fibrosis |
2a |
Galapagos (Belgium) |
Lung diseases - Respiratory diseases - Rare diseases |
2016-04-06
|
MOR208 and lenalidomide |
relapsed or refractory diffuse large B cell lymphoma (DLBCL) |
2 |
MorphoSys (Germany) |
Cancer - Oncology |
2016-04-05
|
Atu027 and gemcitabine |
pancreatic cancer |
1b-2a |
Silence Therapeutics (UK) |
Cancer - Oncology |
2016-04-05
|
BI 1026706 |
macular edema |
2 |
Boehringer Ingelheim (Germany) |
Ophtalmological diseases |
2016-04-04
|
ORY-2001 |
Alzheimer's disease |
1 |
Oryzon Genomics (Spain) |
Neurodegenerative diseases |
2016-04-04
|
masitinib |
amyotrophic lateral sclerosis (ALS) |
3 |
AB Science (France) |
Neurodegenerative diseases - Rare diseases |